Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PERSEVERE: Genomically Directed Therapy for Residual Triple Negative Breast Cancer
NCT04849364Phase 2Terminated
- Sponsor
- Bryan Schneider
- Start
- Aug 2021
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of inavolisib in triple-negative breast cancer (TNBC), sponsored by Bryan Schneider. Started Aug 2021; status: terminated.
02
Drugs
inavolisib
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04849364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04849364.